JP2021050220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021050220A5 JP2021050220A5 JP2020201294A JP2020201294A JP2021050220A5 JP 2021050220 A5 JP2021050220 A5 JP 2021050220A5 JP 2020201294 A JP2020201294 A JP 2020201294A JP 2020201294 A JP2020201294 A JP 2020201294A JP 2021050220 A5 JP2021050220 A5 JP 2021050220A5
- Authority
- JP
- Japan
- Prior art keywords
- pge
- cells
- inflammation
- disease
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 12
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 12
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 8
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims 8
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 229960000890 hydrocortisone Drugs 0.000 claims 6
- -1 phenyl ester Chemical class 0.000 claims 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 5
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 5
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 5
- 229960005205 prednisolone Drugs 0.000 claims 5
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 5
- 239000000556 agonist Substances 0.000 claims 4
- 201000001981 dermatomyositis Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003862 glucocorticoid Substances 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003180 prostaglandins Chemical class 0.000 claims 4
- 210000003491 skin Anatomy 0.000 claims 4
- 150000003384 small molecules Chemical class 0.000 claims 4
- XSGQFHNPNWBVPT-DSFPJDRCSA-N 15-Methyl-15S-PGE2 Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-DSFPJDRCSA-N 0.000 claims 3
- NXMMZTNQIJBMBC-QKIVIXBWSA-N 20-Ethyl-PGE2 Chemical compound CCCCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O NXMMZTNQIJBMBC-QKIVIXBWSA-N 0.000 claims 3
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 229960002537 betamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 3
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 3
- 229960002593 desoximetasone Drugs 0.000 claims 3
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims 3
- 229960003957 dexamethasone Drugs 0.000 claims 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 3
- 229960003469 flumetasone Drugs 0.000 claims 3
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims 3
- 230000001506 immunosuppresive effect Effects 0.000 claims 3
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 229960002842 clobetasol Drugs 0.000 claims 2
- XWTIDFOGTCVGQB-FHIVUSPVSA-N fluocortin butyl Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)C(=O)OCCCC)[C@@]2(C)C[C@@H]1O XWTIDFOGTCVGQB-FHIVUSPVSA-N 0.000 claims 2
- 229960000618 fluprednisolone Drugs 0.000 claims 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- WWMXHYUXIKWXSR-AAHOZRAYSA-N (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H](C(=O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWMXHYUXIKWXSR-AAHOZRAYSA-N 0.000 claims 1
- VHRSUDSXCMQTMA-UHFFFAOYSA-N 11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC12C=CC(=O)C=C1C(C)CC1C2C(O)CC2(C)C(O)(C(=O)CO)CCC21 VHRSUDSXCMQTMA-UHFFFAOYSA-N 0.000 claims 1
- LLVVDFDWPQHXBA-QEJIITRLSA-N 11-Deoxy-16,16-dimethyl-PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1C\C=C/CCCC(O)=O LLVVDFDWPQHXBA-QEJIITRLSA-N 0.000 claims 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 1
- DPNOTBLPQOITGU-LDDQNKHRSA-N 11-deoxyprostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1CCC(=O)[C@@H]1CCCCCCC(O)=O DPNOTBLPQOITGU-LDDQNKHRSA-N 0.000 claims 1
- XSGQFHNPNWBVPT-VFXMVCAWSA-N 15-methyl-15R-PGE2 Chemical compound CCCCC[C@@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XSGQFHNPNWBVPT-VFXMVCAWSA-N 0.000 claims 1
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims 1
- DXWJXQSQVUJRNS-YYWARMNLSA-N 16-Phenyl-tetranor-PGE2 Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H](C(=O)C[C@H]1O)C\C=C/CCCC(O)=O)C1=CC=CC=C1 DXWJXQSQVUJRNS-YYWARMNLSA-N 0.000 claims 1
- FOBVMYJQWZOGGJ-XYRJXBATSA-N 17-phenyl-18,19,20-trinor-prostaglandin E2 Chemical group C([C@H](O)\C=C\[C@@H]1[C@H](C(=O)C[C@H]1O)C\C=C/CCCC(O)=O)CC1=CC=CC=C1 FOBVMYJQWZOGGJ-XYRJXBATSA-N 0.000 claims 1
- WTJYDBMHYPQFNJ-ZUVVJKHESA-N 19R-Hydroxy-PGE2 Chemical compound C[C@@H](O)CCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O WTJYDBMHYPQFNJ-ZUVVJKHESA-N 0.000 claims 1
- CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 claims 1
- AZIGEYVZEVXWAD-NZGURKHLSA-N 20-hydroxyprostaglandin E2 Chemical compound OCCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O AZIGEYVZEVXWAD-NZGURKHLSA-N 0.000 claims 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- YRTJDWROBKPZNV-RSNVZYGJSA-N 8-iso-15-keto-PGE2 Chemical compound CCCCCC(=O)\C=C\[C@H]1[C@H](O)CC(=O)[C@H]1C\C=C/CCCC(O)=O YRTJDWROBKPZNV-RSNVZYGJSA-N 0.000 claims 1
- WMLGLMGSFIXSGO-KTXJXPLISA-N 9-Deoxy-9-methylene-16,16-dimethyl -PGE2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O WMLGLMGSFIXSGO-KTXJXPLISA-N 0.000 claims 1
- VKEJXDXJUFQESA-DLMPNJEASA-N 9-Deoxy-9-methylene-PGE2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=C)[C@@H]1C\C=C/CCCC(O)=O VKEJXDXJUFQESA-DLMPNJEASA-N 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 206010049047 Chapped lips Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012441 Dermatitis bullous Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical group C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010052437 Nasal discomfort Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010051246 Photodermatosis Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 102000007620 Pulmonary Surfactant-Associated Protein C Human genes 0.000 claims 1
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010040799 Skin atrophy Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 241000519995 Stachys sylvatica Species 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 208000032159 Vaginal inflammation Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- CYMBAKFTWRNHPS-APRQOCPKSA-N [2-[(6s,8s,9s,10r,11s,13s,14s,17r)-6-fluoro-11,17-dihydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(=O)C)(O)[C@@]2(C)C[C@@H]1O CYMBAKFTWRNHPS-APRQOCPKSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 210000004404 adrenal cortex Anatomy 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229960000552 alclometasone Drugs 0.000 claims 1
- FJXOGVLKCZQRDN-PHCHRAKRSA-N alclometasone Chemical compound C([C@H]1Cl)C2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O FJXOGVLKCZQRDN-PHCHRAKRSA-N 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 229960003099 amcinonide Drugs 0.000 claims 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 claims 1
- 229960004909 aminosalicylic acid Drugs 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229960000870 betamethasone benzoate Drugs 0.000 claims 1
- SOQJPQZCPBDOMF-YCUXZELOSA-N betamethasone benzoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)C(=O)CO)C(=O)C1=CC=CC=C1 SOQJPQZCPBDOMF-YCUXZELOSA-N 0.000 claims 1
- 229960004311 betamethasone valerate Drugs 0.000 claims 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 1
- 201000005271 biliary atresia Diseases 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229950008654 butaprost Drugs 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 229960004703 clobetasol propionate Drugs 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 1
- 229960004544 cortisone Drugs 0.000 claims 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 claims 1
- 229960003572 cyclobenzaprine Drugs 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229960003662 desonide Drugs 0.000 claims 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229960001162 dihydrostreptomycin sulfate Drugs 0.000 claims 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 1
- 229960004511 fludroxycortide Drugs 0.000 claims 1
- 229940042902 flumethasone pivalate Drugs 0.000 claims 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 claims 1
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 1
- 229960005355 fluocortin Drugs 0.000 claims 1
- 229950008509 fluocortin butyl Drugs 0.000 claims 1
- 229960001048 fluorometholone Drugs 0.000 claims 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims 1
- 229960003590 fluperolone Drugs 0.000 claims 1
- HHPZZKDXAFJLOH-QZIXMDIESA-N fluperolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](OC(C)=O)C)(O)[C@@]1(C)C[C@@H]2O HHPZZKDXAFJLOH-QZIXMDIESA-N 0.000 claims 1
- 229960000671 formocortal Drugs 0.000 claims 1
- QNXUUBBKHBYRFW-QWAPGEGQSA-N formocortal Chemical compound C1C(C=O)=C2C=C(OCCCl)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O QNXUUBBKHBYRFW-QWAPGEGQSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 229960002383 halcinonide Drugs 0.000 claims 1
- 229960002475 halometasone Drugs 0.000 claims 1
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 229960001067 hydrocortisone acetate Drugs 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- XVQUOJBERHHONY-UHFFFAOYSA-N isometheptene Chemical compound CNC(C)CCC=C(C)C XVQUOJBERHHONY-UHFFFAOYSA-N 0.000 claims 1
- 229960003046 isometheptene Drugs 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 208000018937 joint inflammation Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960001011 medrysone Drugs 0.000 claims 1
- XRISENIKJUKIHD-LHQZMKCDSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(e,4r)-4-hydroxy-4-(1-propylcyclobutyl)but-1-enyl]-5-oxocyclopentyl]heptanoate Chemical compound CCCC1([C@H](O)C\C=C\[C@@H]2[C@H](C(=O)C[C@H]2O)CCCCCCC(=O)OC)CCC1 XRISENIKJUKIHD-LHQZMKCDSA-N 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 229960002037 methylprednisolone aceponate Drugs 0.000 claims 1
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 claims 1
- 229960001293 methylprednisolone acetate Drugs 0.000 claims 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 229960004123 mometasone furoate monohydrate Drugs 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 210000001331 nose Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 230000008845 photoaging Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 229930182884 serinolamide Natural products 0.000 claims 1
- 238000010008 shearing Methods 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 230000002966 stenotic effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 1
- 210000005239 tubule Anatomy 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 229940070710 valerate Drugs 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023010327A JP2023052658A (ja) | 2015-01-26 | 2023-01-26 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107517P | 2015-01-26 | 2015-01-26 | |
| US62/107,517 | 2015-01-26 | ||
| US201562112653P | 2015-02-06 | 2015-02-06 | |
| US62/112,653 | 2015-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539018A Division JP2018504122A (ja) | 2015-01-26 | 2016-01-26 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023010327A Division JP2023052658A (ja) | 2015-01-26 | 2023-01-26 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021050220A JP2021050220A (ja) | 2021-04-01 |
| JP2021050220A5 true JP2021050220A5 (enExample) | 2021-06-10 |
Family
ID=56544240
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539018A Withdrawn JP2018504122A (ja) | 2015-01-26 | 2016-01-26 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
| JP2020201294A Pending JP2021050220A (ja) | 2015-01-26 | 2020-12-03 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
| JP2020201293A Active JP7304844B2 (ja) | 2015-01-26 | 2020-12-03 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
| JP2023010327A Pending JP2023052658A (ja) | 2015-01-26 | 2023-01-26 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
| JP2023025696A Pending JP2023062155A (ja) | 2015-01-26 | 2023-02-22 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539018A Withdrawn JP2018504122A (ja) | 2015-01-26 | 2016-01-26 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201293A Active JP7304844B2 (ja) | 2015-01-26 | 2020-12-03 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
| JP2023010327A Pending JP2023052658A (ja) | 2015-01-26 | 2023-01-26 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
| JP2023025696A Pending JP2023062155A (ja) | 2015-01-26 | 2023-02-22 | 免疫調節特性が増加した細胞ならびにその使用および製造のための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20180112180A1 (enExample) |
| EP (2) | EP3250682A4 (enExample) |
| JP (5) | JP2018504122A (enExample) |
| CN (2) | CN107429232B (enExample) |
| AU (3) | AU2016211688A1 (enExample) |
| CA (1) | CA2974903A1 (enExample) |
| WO (1) | WO2016123117A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114058582A (zh) | 2015-01-26 | 2022-02-18 | 菲特治疗公司 | 用于诱导造血细胞分化的方法和组合物 |
| CA2993201A1 (en) | 2015-07-21 | 2017-01-26 | The Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
| EP3371301A4 (en) | 2015-11-04 | 2019-06-26 | Fate Therapeutics, Inc. | METHOD AND COMPOSITIONS FOR INDUCING THE DIFFERENTIATION OF HEMATOPOIETIC CELLS |
| CN115806940A (zh) | 2015-11-04 | 2023-03-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
| KR102878032B1 (ko) * | 2016-01-20 | 2025-10-28 | 페이트 세러퓨틱스, 인코포레이티드 | 입양 면역요법에서 면역 세포 조절을 위한 조성물 및 방법 |
| JP7653759B2 (ja) | 2016-01-20 | 2025-03-31 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US9918994B2 (en) | 2016-03-04 | 2018-03-20 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin E2 |
| JP7098615B2 (ja) | 2016-12-05 | 2022-07-11 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| WO2018227134A1 (en) | 2017-06-09 | 2018-12-13 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for preventing or treating muscle conditions |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| CN107714717A (zh) * | 2017-10-11 | 2018-02-23 | 刘志强 | 聚肌胞苷酸在制备治疗或预防结肠炎的药物中的应用 |
| CN111712565A (zh) * | 2018-02-16 | 2020-09-25 | 奈科斯特细胞制药有限公司 | 同种异体组合物 |
| EP3863650A4 (en) * | 2018-10-10 | 2022-09-14 | North Carolina State University | PRESENTATION BLISTERS OF PD-L1 TO REVERSE NEW ONSET OF TYPE 1 DIABETES |
| WO2020077204A1 (en) * | 2018-10-12 | 2020-04-16 | Salk Institute For Biological Studies | Cells, islets, and organoids that evade immune detection and autoimmunity, methods of production and use thereof |
| CN109706180A (zh) * | 2019-01-11 | 2019-05-03 | 杭州荣泽生物科技有限公司 | 一种脐带间充质干细胞过表达ido增强免疫抑制的方法及应用 |
| AU2020219097A1 (en) * | 2019-02-09 | 2021-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Genetically modified hematopoietic stem and progenitor cells (HSPCs) and mesenchymal cells as a platform to reduce or prevent metastasis, treat autoimmune and inflammatory disorders, and rebalance the immune milieu and dysregulated niches |
| EP3994245A1 (en) * | 2019-07-05 | 2022-05-11 | Case Western Reserve University | Priming media and methods for stem cell culture and therapy |
| EP4106764A1 (en) * | 2020-02-18 | 2022-12-28 | Octagon Therapeutics Inc. | Immune cell modulators |
| WO2021263097A2 (en) * | 2020-06-26 | 2021-12-30 | The Children's Medical Center Corporation | Methods and compositions for treating multiple sclerosis |
| JP7776486B2 (ja) * | 2020-07-08 | 2025-11-26 | ザ ジャクソン ラボラトリー | ヒトｈｌａ－ａ２０１制限遺伝子を発現するトランスジェニックマウスモデル |
| CN117043661A (zh) | 2021-03-24 | 2023-11-10 | 佳能株式会社 | 虚拟图像光学系统、包括虚拟图像光学系统的虚拟图像显示设备以及车载系统 |
| KR20220162394A (ko) * | 2021-06-01 | 2022-12-08 | 에스씨엠생명과학 주식회사 | 기능강화 줄기세포 및 조절 t 세포를 포함하는 아토피 피부염 예방 또는 치료용 병용투여 조성물 |
| WO2025043075A1 (en) * | 2023-08-24 | 2025-02-27 | The Johns Hopkins University | Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury |
| WO2025199431A1 (en) * | 2024-03-22 | 2025-09-25 | Colorado State University Research Foundation | Innate immune pathway activated mesenchymal stromal cells for treatment of musculoskeletal disorders or conditions |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| WO2000038663A2 (en) | 1998-12-24 | 2000-07-06 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| ATE327751T1 (de) | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| WO2003087347A1 (en) * | 2002-04-12 | 2003-10-23 | Medical College Of Georgia Research Institute, Inc. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| US7763251B2 (en) * | 2002-04-12 | 2010-07-27 | Medical College Of Georgia Research Institute, Inc. | Kits to assess the risk of tumor progression |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| WO2005040391A1 (en) | 2003-10-27 | 2005-05-06 | Murdoch Childrens Research Institute | Compositions and methods for differentiating stem cells |
| ES2398239T3 (es) | 2003-11-10 | 2013-03-14 | The Scripps Research Institute | Composiciones y procedimientos para inducir la desdiferenciación celular |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| JP5537153B2 (ja) * | 2006-11-03 | 2014-07-02 | アストロム バイオサイエンシーズ， インコーポレイテッド | 組織修復のための混合細胞集団および細胞処理のための単離技術 |
| CA2683056C (en) | 2007-04-07 | 2020-03-24 | Whitehead Institute For Biomedical Research | Reprogramming of somatic cells |
| AU2008287063B2 (en) * | 2007-08-09 | 2013-10-24 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| MX2010002242A (es) | 2007-08-31 | 2010-06-01 | Whitehead Biomedical Inst | Estimulación de ruta wnt en reprogramacion de celulas somaticas. |
| SG188904A1 (en) | 2008-03-17 | 2013-04-30 | Scripps Research Inst | Combined chemical and genetic approaches for generation of induced pluripotent stem cells |
| WO2011087637A1 (en) * | 2009-12-08 | 2011-07-21 | The Board Of Trustees Of The University Of Illinois | Stem cell immune modulation methods of use and apparatus |
| MX340972B (es) * | 2008-10-08 | 2016-08-02 | Intrexon Corp | Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas. |
| EP3031907B1 (en) | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| EP3312269A1 (en) | 2008-12-17 | 2018-04-25 | The Scripps Research Institute | Generation and maintenance of stem cells |
| JP5836262B2 (ja) | 2009-03-19 | 2015-12-24 | フェイト セラピューティクス， インコーポレイテッド | サイクリックａｍｐエンハンサーおよび／またはｅｐリガンドを含む組成物、ならびにこれを調製および使用する方法 |
| TR201819229T4 (tr) * | 2009-07-24 | 2019-01-21 | Immune Design Corp | Entegre olmayan lentiviral vektörler. |
| CN105861446B (zh) | 2009-10-16 | 2021-10-01 | 斯克里普斯研究所 | 多能细胞的诱导 |
| CA2780572A1 (en) * | 2009-11-13 | 2011-05-19 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Modulated programmed death ligand-1 |
| TWI688395B (zh) * | 2010-03-23 | 2020-03-21 | 英翠克頌公司 | 條件性表現治療性蛋白質之載體、包含該載體之宿主細胞及彼等之用途 |
| CA3079122A1 (en) * | 2010-03-26 | 2011-09-29 | Trustees Of Dartmouth College | Vista regulatory t cell mediator protein, vista binding agents and use thereof |
| CA2807944C (en) * | 2010-08-12 | 2020-02-18 | Fate Therapeutics, Inc. | Improved hematopoietic stem and progenitor cell therapy |
| WO2013040552A2 (en) * | 2011-09-16 | 2013-03-21 | Georgia Health Sciences University | Methods of promoting immune tolerance |
| EP3785767A1 (en) * | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| US20150139994A1 (en) * | 2013-11-12 | 2015-05-21 | The Regents Of The University Of California | Compositions and methods for preventing allogeneic immune rejection |
| CA2993201A1 (en) * | 2015-07-21 | 2017-01-26 | The Children's Medical Center Corporation | Pd-l1 expressing hematopoietic stem cells and uses |
-
2016
- 2016-01-26 WO PCT/US2016/014942 patent/WO2016123117A1/en not_active Ceased
- 2016-01-26 JP JP2017539018A patent/JP2018504122A/ja not_active Withdrawn
- 2016-01-26 EP EP16743971.0A patent/EP3250682A4/en not_active Withdrawn
- 2016-01-26 CN CN201680018098.0A patent/CN107429232B/zh active Active
- 2016-01-26 US US15/546,255 patent/US20180112180A1/en not_active Abandoned
- 2016-01-26 CN CN202011413164.9A patent/CN112481211B/zh active Active
- 2016-01-26 EP EP20193805.7A patent/EP3770252A1/en active Pending
- 2016-01-26 CA CA2974903A patent/CA2974903A1/en active Pending
- 2016-01-26 AU AU2016211688A patent/AU2016211688A1/en not_active Abandoned
-
2019
- 2019-12-02 US US16/701,013 patent/US20200172870A1/en not_active Abandoned
- 2019-12-02 US US16/700,990 patent/US20200102540A1/en not_active Abandoned
-
2020
- 2020-12-03 JP JP2020201294A patent/JP2021050220A/ja active Pending
- 2020-12-03 JP JP2020201293A patent/JP7304844B2/ja active Active
-
2021
- 2021-04-20 AU AU2021202391A patent/AU2021202391B2/en active Active
- 2021-05-28 AU AU2021203480A patent/AU2021203480A1/en not_active Abandoned
-
2022
- 2022-08-25 US US17/895,697 patent/US20230002733A1/en not_active Abandoned
-
2023
- 2023-01-26 JP JP2023010327A patent/JP2023052658A/ja active Pending
- 2023-02-22 JP JP2023025696A patent/JP2023062155A/ja active Pending
-
2024
- 2024-04-11 US US18/632,967 patent/US20250101381A1/en not_active Abandoned
- 2024-12-11 US US18/977,377 patent/US20250333702A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021050220A5 (enExample) | ||
| JP2018504122A5 (enExample) | ||
| JP2019047820A5 (enExample) | ||
| AU2021202391B2 (en) | Cells with increased immuno-regulatory properties and methods for their use and manufacture | |
| JP2017136094A5 (enExample) | ||
| JP2018197259A5 (enExample) | ||
| RU2648475C2 (ru) | Терапевтическое применение эктоина | |
| JP2008297310A (ja) | 少なくとも１つのビタミンｄまたは１つのビタミンｄアナログおよび少なくとも１つのコルチコステロイドを含有する局所用組成物 | |
| CN1351499A (zh) | 药物组合物 | |
| ES2991544T3 (es) | Ketamina para el tratamiento de síntomas relacionados con la menstruación | |
| JP2008297309A5 (enExample) | ||
| US8829024B2 (en) | Combination steroid and glucocorticoid receptor antagonist therapy | |
| HRP20161268T1 (hr) | Kombinirani preparat koji se sastoji od egzozoma i kortikosteroida | |
| JP2006518382A5 (enExample) | ||
| JPWO2020112889A5 (enExample) | ||
| WO1997015298A1 (en) | Combination of ltd, receptor antagonists with glucocorticosteroids | |
| JPH0571568B2 (enExample) | ||
| JPWO2020181060A5 (enExample) | ||
| US5358943A (en) | Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids | |
| WO2023119239A1 (en) | Method of treating severe graft versus host disease | |
| GB2624353A (en) | Novel Omega 3 carrier preparations for inhalation drug delivery for treating lung inflammation | |
| US12023344B2 (en) | Topical otic, ophthalmic, and nasal corticosteroid formulations | |
| DK2538922T3 (en) | The formulation of compositions for the treatment of inflammatory conditions | |
| Adcock et al. | Corticosteroids | |
| CN112386599A (zh) | 一种丁酸氢化可的松外用制剂 |